Division of Immunization, Korea Disease Control and Prevention Agency, Cheongju, Korea.
KDI School of Public Policy and Management, Sejong, Korea.
J Korean Med Sci. 2024 Aug 19;39(32):e235. doi: 10.3346/jkms.2024.39.e235.
On May 1, 2024, the Republic of Korea lifted the infectious disease crisis alert for mpox, almost two years after the first case was reported. The Korea Disease Control and Prevention Agency (KDCA) has led the response, which included diagnosis, epidemiological investigations, treatment, and vaccination. This article particularly reviews the vaccination strategy implemented and proposes suggestions for enhancing future response efforts. Initially, the KDCA recommended pre-exposure prophylaxis for high-risk groups, later expanding to include broader demographics as domestic cases rose. By April 2024, a total of 6,863 individuals had received their first vaccine dose, with 3,875 completing the second dose of third-generation vaccines. Strategies to improve future responses include addressing stigma, securing nationally representative safety data, and conducting vaccine cost-benefit analyses. These measures will help ensure a robust and effective response to future outbreaks.
2024 年 5 月 1 日，韩国解除了猴痘传染病危机警报，距离首例病例报告已过去近两年。韩国疾病管理厅 (KDCA) 一直主导着应对工作，包括诊断、流行病学调查、治疗和疫苗接种。本文特别回顾了实施的疫苗接种策略，并为加强未来应对工作提出建议。最初，KDCA 建议对高危人群进行暴露前预防，后来随着国内病例的增加，扩大到包括更广泛的人群。截至 2024 年 4 月，共有 6863 人接种了第一剂疫苗，其中 3875 人完成了第三代疫苗的第二剂接种。改善未来应对策略包括解决污名化问题、确保具有全国代表性的安全数据以及进行疫苗成本效益分析。这些措施将有助于确保对未来疫情做出强有力和有效的反应。
